1300hrs webinar 30 September22 Sep 2021 01:10
The company clearly has something important to say. It will be 8am in New York and some trial sites in USA could follow it if they tuned in early. A lot of effort usually goes into a webinar and the purpose is usually to heighten transparency between the company, its stakeholders and this includes investors. The probability is Synairgen has some kind of new data to share with us. It might concern long Covid-19 avoidance in some cases, or extending a study against the mu variant in Colombia or whatever. It may also be a case of running through the road map of what may follow if the trial is successful. I am not sure of any occasions when bad news is delivered by a webinar Q&A without a prior RNS. It is far more likely that engaging analysts would only take part if the data to be presented was having a meaningful impact as it would enable them to raise constructive questions about route to market, future financing, the value to patients and would this be the key to avoid UK lockdowns etcetera and issues about manufacturing to meet healthcare demands. It does not make a lot of sense to invite analysts to dissect a study that failed to meet its endpoints or did not have adequate efficacy. At any rate we have an interesting day in the diary to look forward to. Tony